Throughout an investigation of rivers in Bulgaria, an isolate of Phytophthora (RLKam2016/61c) was recovered and initially recognized as Phytophthora sansomeana primarily based on inside transcribed spacer area (ITS) sequence information.
Nevertheless, the sequencing of the mitochondrial cytochrome c oxidase subunit I (cox1) gene revealed excessive similarity to Phytophthora sp. kelmania, and sequencing of different nuclear areas (β-tubulin [Btub] and translation elongation issue 1-alpha [tef1]) revealed a big variety of polymorphisms, indicating a attainable hybridization occasion.
Extra cloning and sequencing of the nuclear ITS and Btub areas confirmed the presence of two distinct teams of alleles, one in every of which was extremely much like P. sansomeana, whereas the opposite was much like a species advanced that features Phytophthora sp. kelmania. Due to this fact, the brand new hybrid was named Phytophthora × sansomeana.
It’s characterised by quick development on V8 juice agar (V8A) and carrot agar (CA), average aerial mycelium with radiate sample of the colonies and comparatively slower development fee on malt extract agar (MEA) and potato dextrose agar (PDA), and petaloid to rosaceous sample of the colonies with fluffy aerial mycelium. The optimum development temperature for P. × sansomeana was at 25 C, with a median development fee of 9 mm per day. Considerable sporangium formation of the isolate in spring water was noticed, however the hybrid was sterile in tradition.
Pathogenicity analyses of the hybrid have been carried out compared with probably the most carefully associated subclade 8a species from our assortment, P. pseudocryptogea. The inhibition impact on the basis development of younger seedlings of two legumes, frequent pea and vetch, in addition to on cuttings of the decorative plant coleus induced by each phytopathogens was important. No impact of both the brand new hybrid or P. pseudocryptogea on the expansion of maize seedlings was noticed.
Pure genetic range within the potato resistance gene RB confers suppression avoidance from Phytophthora effector IPI-O4
RB is a potato gene that gives resistance to a broad spectrum of genotypes of the late blight pathogen Phytophthora infestans. RB belongs to the CC-NB-LRR (coiled-coil, nucleotide-binding, leucine-rich repeat) class of resistance (R) genes, a serious part of the plant immune system.
The RB protein detects the presence of Class I and II IPI-O effectors from P. infestans to provoke a hypersensitive resistance response, however this exercise is suppressed within the presence of the Class III effector IPI-O4. Utilizing pure genetic variation of RB inside potato wild family, we recognized two amino acids within the CC area that alter interactions wanted for suppression of resistance by IPI-O4.
We have now discovered that separate modification of those amino acids in RB can diminish or develop the resistance functionality of this protein in opposition to P. infestans in each Nicotiana benthamiana and potato. Our outcomes show that elevated data of the molecular mechanisms that decide resistance activation and R protein suppression by effectors may be utilized to tailor-engineer genes with the potential to offer elevated sturdiness.
Focusing on of anti-microbial proteins to the hyphal floor amplifies safety of crop vegetation in opposition to Phytophthora pathogens
Phytophthora pathogens are a persistent menace to the world’s commercially essential agricultural crops, together with potato and soybean. Present methods geared toward lowering crop losses rely totally on illness resistance breeding and chemical pesticides, which may be often overcome by the speedy adaptive evolution of pathogens.
Transgenic crops with intrinsic illness resistance supply a promising different and proceed to be developed. Right here, we used Phytophthora-derived PI3P (phosphatidylinositol 3-phosphate) as a novel management goal, utilizing proteins that bind this lipid to direct secreted antimicrobial peptides and proteins (AMPs) to the floor of the pathogen.
In transgenic Nicotiana benthamiana, soybean, and potato vegetation, considerably enhanced resistance to totally different pathogen isolates was achieved by expression of two AMPs (GAFP1 or GAFP3 from the Chinese language medicinal herb Gastrodia elata) fused with a PI3P-specific binding area (FYVE). Utilizing the soybean pathogen P. sojae for example, we demonstrated that the FYVE area may enhance the actions of the GAFPs in a number of unbiased assays, together with in vitro, in vivo, and in planta.
Mutational evaluation of the PI3K1 and PI3K2 genes of this pathogen confirmed that the improved actions of the focused GAFPs have been correlated with PI3P ranges within the pathogen. The technique could possibly be used in opposition to Phytophthora pathogens of many vegetation, and for different kinds of plant pathogens with distinctive targets.
Late blight in tomato: insights into the pathogenesis of the aggressive pathogen Phytophthora infestans and future analysis priorities
This assessment supplies insights into the molecular interactions between Phytophthora infestans and tomato and highlights analysis gaps that want additional consideration. Late blight in tomato is attributable to the oomycota hemibiotroph Phytophthora infestans, and this illness represents a world menace to tomato farming.
The pathogen is cumbersome to regulate due to its fast-evolving nature, capability to beat host resistance and inefficient pure resistance obtained from the obtainable tomato germplasm. To realize profitable management over this pathogen, the molecular pathogenicity of P. infestans and key factors of vulnerability within the host plant immune system should be understood.
FGF-acidic Recombinant Protein |
40-543-005mg |
ProSci |
0.05 mg |
EUR 437.1 |
Description: FGF-acidic is one of 23 known members of the FGF family. Proteins of this family play a central role during prenatal development, postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-acidic is a non-glycosylated heparin binding growth factor that is expressed in the brain, kidney, retina, smooth muscle cells, bone matrix, osteoblasts, astrocytes and endothelial cells. FGF-acidic has the ability to signal through all the FGF receptors. Recombinant rat FGF-acidic is a 15.9 kDa protein consisting of 141 amino acid residues. |
FGF-acidic Recombinant Protein |
40-588 |
ProSci |
0.05 mg |
EUR 481.2 |
Description: FGF-acidic is one of 23 known members of the FGF family. Proteins of this family play a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-acidic is a non-glycosylated heparin binding growth factor that is expressed in the brain, kidney, retina, smooth muscle cells, bone matrix, osteoblasts, astrocytes and endothelial cells. FGF-acidic has the ability to signal through all the FGF receptors. Recombinant human FGF-acidic is a 15.8 kDa protein consisting of 140 amino acid residues. |
Recombinant Human FGF-acidic Protein |
PROTP05230-2 |
BosterBio |
50ug |
EUR 380.4 |
Description: FGF-acidic is one of 23 known members of the FGF family. Proteins of this family play a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-acidic is a non-glycosylated heparin binding growth factor that is expressed in the brain, kidney, retina, smooth muscle cells, bone matrix, osteoblasts, astrocytes and endothelial cells. FGF-acidic has the ability to signal through all the FGF receptors. Recombinant human FGF-acidic is a 16.0 kDa protein consisting of 141 amino acid residues. |
Recombinant Murine FGF-acidic Protein |
PROTP61148-2 |
BosterBio |
50ug |
EUR 380.4 |
Description: FGF-acidic is one of 23 known members of the FGF family. Proteins of this family play a central role during prenatal development and postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-acidic is a non-glycosylated heparin binding growth factor that is expressed in the brain, kidney, retina, smooth muscle cells, bone matrix, osteoblasts, astrocytes and endothelial cells. FGF-acidic has the ability to signal through all the FGF receptors. Recombinant murine FGF-acidic is a 15.9 kDa protein consisting of 141 amino acid residues. |
Recombinant Rat FGF-acidic Protein |
PROTP61149-1 |
BosterBio |
50ug |
EUR 380.4 |
Description: FGF-acidic is one of 23 known members of the FGF family. Proteins of this family play a central role during prenatal development, postnatal growth and regeneration of a variety of tissues, by promoting cellular proliferation and differentiation. FGF-acidic is a non-glycosylated heparin binding growth factor that is expressed in the brain, kidney, retina, smooth muscle cells, bone matrix, osteoblasts, astrocytes and endothelial cells. FGF-acidic has the ability to signal through all the FGF receptors. Recombinant rat FGF-acidic is a 15.9 kDa protein consisting of 141 amino acid residues. |
Recombinant Human Annexin A1 |
7-04319 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human Annexin A1 |
7-04320 |
CHI Scientific |
100µg |
Ask for price |
Annexin A1 Recombinant Protein |
91-076 |
ProSci |
0.05 mg |
EUR 821.4 |
Description: Annexin A1 is the first characterized member of the annexin family of proteins and is able to bind to cellular membranes in a calcium-dependent manner, promoting membrane fusion and endocytosis. Annexin A1 has anti-inflammatory properties and inhibits phospholipase A2 activity. Annexin A1 also has roles in many diverse cellular functions, such as membrane aggregation, inflammation, phagocytosis, proliferation, apoptosis, and tumorigenesis and cancer development. ANXA1 is strongly expressed on the cell membrane and occasionally in the cytoplasm of tumor cells in 97% of samples from patients with hairy cell leukemia. |
Serpin A1 Recombinant Protein |
91-483 |
ProSci |
0.05 mg |
EUR 821.4 |
Description: Serpin A1 is a prototype member of the Serpin superfamily of the serine protease inhibitors. As one of the most abundant proteinase inhibitors in the circulation, it is synthesized in hepatocytes, and to a lesser extent, in macrophages as well as intestinal epithelial cell lines and secreted as the abundant proteinase inhibitor in the circulation whose targets include elastase, plasmin, thrombin, trypsin, chymotrypsin, and plasminogen activator. Point mutations in the native SerpinA1 variants result in Serpin A1 deficiency, and consequently lead to several clinical complications such as pulmonary emphysema, juvenile hepatitis, cirrhosis, and hepatocellular carcinoma. For example, the Z variants (Glu342 to Lys) forms intracellular inclusion bodies, is not secreted, and leads to a severe SerpinA1 deficiency. Accordingly, Serpin A1 deficiency in circulation is associated with emphysema or liver disease. |
Carboxypeptidase A1 Recombinant Protein |
91-528 |
ProSci |
0.05 mg |
EUR 852.9 |
Description: Carboxypeptidase A1 (CPA1) is secreted as a pancreatic peptidase that comes from the precursor form of inactive procarboxypeptidase. CPA1 comprises a signal peptide, a pro region and a mature chain, and can be activated after cleavage of the pro peptide. It has a free C-terminal carboxyl group, with the preference of residues with aromatic or branched aliphatic side chains. CPA1 cleaves the C-terminal amide or ester bond of peptides and involves in zymogen inhibition. Three different forms of human pancreatic procarboxypeptidase A have been isolated. In contrast to procarboxypeptidase B which was always secreted by the pancreas as a monomer, procarboxypeptidase A occurs as a monomer and/or associated to one or two functionally different proteins, such as zymogen E. |
Ephrin-A1 Recombinant Protein |
91-770 |
ProSci |
0.05 mg |
EUR 651.3 |
Description: Ephrin-A1 is a member of the A-type ephrin family of cell surface proteins that function as ligands for the A-type Eph receptor tyrosine kinase family. Ephrin-A1 can be induced by TNF and IL1B. Its expression levels can be down-regulated in primary glioma tissues compared to the normal tissues. The soluble monomeric form is expressed in the glioblastoma multiforme (GBM) and breast cancer cells. Soluble Ephrin-A1 is necessary for the transformation of HeLa and SK-BR3 cells and participates in the relocalization of EPHA2 away from sites of cell-cell contact during transformation. Ephrin-A1 plays an important role in angiogenesis and tumor neovascularization. |
Ephrin-A1 Recombinant Protein |
91-935 |
ProSci |
0.05 mg |
EUR 588.3 |
Description: Ephrin-A1 is a member of the A-type ephrin family of cell surface proteins that function as ligands for the A-type Eph receptor tyrosine kinase family. Ephrin-A1 can be induced by TNF and IL1B. Its expression levels can be down-regulated in primary glioma tissues compared to the normal tissues. The soluble monomeric form is expressed in the glioblastoma multiforme (GBM) and breast cancer cells. Soluble Ephrin-A1 is necessary for the transformation of HeLa and SK-BR3 cells and participates in the relocalization of EPHA2 away from sites of cell-cell contact during transformation. Ephrin-A1 plays an important role in angiogenesis and tumor neovascularization. |
Ephrin-A1 Recombinant Protein |
91-945 |
ProSci |
0.05 mg |
EUR 374.1 |
Description: Ephrin-A1 is a cell membrane protein and contains 1 ephrin RBD (ephrin receptor-binding) domain. EFNA1 belongs to the ephrin (EPH) family. The ephrins and EPH-related receptors comprise the largest subfamily of receptor protein-tyrosine kinases and have been implicated in mediating developmental events, especially in the nervous system and in erythropoiesis. Based on their structures and sequence relationships, ephrins are divided into the ephrin-A (EFNA) class, which are anchored to the membrane by a glycosylphosphatidylinositol linkage, and the ephrin-B (EFNB) class, which are transmembrane proteins. This gene encodes an EFNA class ephrin which binds to the EPHA2, EPHA4, EPHA5, EPHA6, and EPHA7 receptors. Two transcript variants that encode different isoforms were identified through sequence analysis.It belongs to the ephrin family and contains 1 ephrin RBD (ephrin receptor-binding) domain. |
Apo A1 Recombinant Protein |
96-031 |
ProSci |
0.05 mg |
EUR 682.8 |
Description: ApoA1 is also known as apolipoprotein A-I, ApoA-I , and is the major protein component of high density lipoprotein (HDL) in plasma. It has a specific role in lipid metabolism. Chylomicrons secreted from the intestinal enterocyte also contain ApoA1 but it is quickly transferred to HDL in the bloodstream. The protein promotes cholesterol efflux from tissues to the liver for excretion. It is a cofactor for lecithin cholesterol acyltransferase (LCAT) which is responsible for the formation of most plasma cholesteryl esters. ApoA-I was also isolated as a prostacyclin (PGI2) stabilizing factor, and thus may have an anticlotting effect. Defects in the gene encoding it are associated with HDL deficiencies, including Tangier disease, and with systemic non-neuropathic amyloidosis. In addition, it has been shown that ApoA1 is implicated in the anti-endotoxin function of HDL via interaction with lipopolysaccharide or endotoxin. |
Ephrin A1 Recombinant Protein |
96-256 |
ProSci |
0.1 mg |
EUR 588.3 |
Description: Ephrin-A1 (EFNA1) is also known as EPLG1, LERK1, TNFAIP4, Immediate early response protein B61, which belongs to the ephrin family. EFNA1 contains one ephrin RBD (ephrin receptor-binding) domain. EFNA1 is cell surface GPI-bound ligand for Eph receptors, and is a family of receptor tyrosine kinases which are crucial for migration, repulsion and adhesion during neuronal, vascular and epithelial development. EFNA1 binds promiscuously Eph receptors residing on adjacent cells, leading to contact-dependent bidirectional signaling into neighboring cells. EFNA1 plays an important role in angiogenesis and tumor neovascularization. |
Serpin A1 Recombinant Protein |
96-681 |
ProSci |
0.05 mg |
EUR 619.8 |
Description: Serpin A1 is also known as Alpha-1-antitrypsin (A1AT), serum trypsin inhibitor, alpha-1 proteinase inhibitor (A1PI), AAT, which belongs to the serpin family. Most serpins inactivate enzymes by binding to them covalently, requiring very high levels to perform their function. Like all serine protease inhibitors, A1AT has a characteristic secondary structure of beta sheets and alpha helices. Serpin A1 / A1AT is inhibitor of serine proteases. Its primary target is elastase, but it also has a moderate affinity for plasmin and thrombin. Irreversibly inhibits trypsin, chymotrypsin and plasminogen activator. The aberrant form of SerpinA1 inhibits insulin-induced NO synthesis in platelets, decreases coagulation time and has proteolytic activity against insulin and plasmin. Serpin A1 / A1AT protects tissues from enzymes of inflammatory cells, especially neutrophil elastase. Defects in SERPINA1 are the cause of alpha-1-antitrypsin deficiency (A1ATD). |
Recombinant human Plexin-A1 |
P1674 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human Plexin-A1 |
Recombinant human Ephrin-A1 |
P1736 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human Ephrin-A1 |
Recombinant Apolipoprotein A1 (APOA1) |
4-RPA519Hu01 |
Cloud-Clone |
-
EUR 442.56
-
EUR 242.40
-
EUR 1329.60
-
EUR 523.20
-
EUR 926.40
-
EUR 372.00
-
EUR 3144.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Apolipoprotein A1 expressed in: E.coli |
Recombinant Apolipoprotein A1 (APOA1) |
4-RPA519Mu01 |
Cloud-Clone |
-
EUR 593.09
-
EUR 282.00
-
EUR 1894.08
-
EUR 711.36
-
EUR 1302.72
-
EUR 472.80
-
EUR 4555.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Apolipoprotein A1 expressed in: E.coli |
Recombinant Apolipoprotein A1 (APOA1) |
4-RPA519Po01 |
Cloud-Clone |
-
EUR 560.83
-
EUR 273.60
-
EUR 1773.12
-
EUR 671.04
-
EUR 1222.08
-
EUR 451.20
-
EUR 4252.80
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Pig Apolipoprotein A1 expressed in: E.coli |
Recombinant Apolipoprotein A1 (APOA1) |
4-RPA519Po02 |
Cloud-Clone |
-
EUR 571.58
-
EUR 276.00
-
EUR 1813.44
-
EUR 684.48
-
EUR 1248.96
-
EUR 458.40
-
EUR 4353.60
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Pig Apolipoprotein A1 expressed in: E.coli |
Recombinant Apolipoprotein A1 (APOA1) |
4-RPA519Rb01 |
Cloud-Clone |
-
EUR 550.08
-
EUR 271.20
-
EUR 1732.80
-
EUR 657.60
-
EUR 1195.20
-
EUR 444.00
-
EUR 4152.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rabbit Apolipoprotein A1 expressed in: E.coli |
Recombinant Plexin A1 (PLXNA1) |
4-RPH354Hu01 |
Cloud-Clone |
-
EUR 601.69
-
EUR 284.40
-
EUR 1926.34
-
EUR 722.11
-
EUR 1324.22
-
EUR 477.60
-
EUR 4635.84
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Plexin A1 expressed in: E.coli |
Recombinant Phospholipase A1 (PLA1) |
4-RPB151Hu01 |
Cloud-Clone |
-
EUR 593.09
-
EUR 282.00
-
EUR 1894.08
-
EUR 711.36
-
EUR 1302.72
-
EUR 472.80
-
EUR 4555.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Phospholipase A1 expressed in: E.coli |
Recombinant Phospholipase A1 (PLA1) |
4-RPB151Hu02 |
Cloud-Clone |
-
EUR 593.09
-
EUR 282.00
-
EUR 1894.08
-
EUR 711.36
-
EUR 1302.72
-
EUR 472.80
-
EUR 4555.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Phospholipase A1 expressed in: E.coli |
Recombinant Ephrin A1 (EFNA1) |
4-RPE107Hu01 |
Cloud-Clone |
-
EUR 588.79
-
EUR 280.80
-
EUR 1877.95
-
EUR 705.98
-
EUR 1291.97
-
EUR 469.20
-
EUR 4514.88
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Ephrin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Gu01 |
Cloud-Clone |
-
EUR 507.07
-
EUR 259.20
-
EUR 1571.52
-
EUR 603.84
-
EUR 1087.68
-
EUR 415.20
-
EUR 3748.80
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Guinea pig Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Hu01 |
Cloud-Clone |
-
EUR 528.58
-
EUR 265.20
-
EUR 1652.16
-
EUR 630.72
-
EUR 1141.44
-
EUR 429.60
-
EUR 3950.40
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Mu01 |
Cloud-Clone |
-
EUR 550.08
-
EUR 271.20
-
EUR 1732.80
-
EUR 657.60
-
EUR 1195.20
-
EUR 444.00
-
EUR 4152.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Po01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Pig Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Ra01 |
Cloud-Clone |
-
EUR 550.08
-
EUR 271.20
-
EUR 1732.80
-
EUR 657.60
-
EUR 1195.20
-
EUR 444.00
-
EUR 4152.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Ra02 |
Cloud-Clone |
-
EUR 550.08
-
EUR 271.20
-
EUR 1732.80
-
EUR 657.60
-
EUR 1195.20
-
EUR 444.00
-
EUR 4152.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Rb01 |
Cloud-Clone |
-
EUR 442.56
-
EUR 242.40
-
EUR 1329.60
-
EUR 523.20
-
EUR 926.40
-
EUR 372.00
-
EUR 3144.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rabbit Annexin A1 expressed in: E.coli |
Recombinant Annexin A1 (ANXA1) |
4-RPE787Rb02 |
Cloud-Clone |
-
EUR 442.56
-
EUR 242.40
-
EUR 1329.60
-
EUR 523.20
-
EUR 926.40
-
EUR 372.00
-
EUR 3144.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rabbit Annexin A1 expressed in: E.coli |
Recombinant Cyclin A1 (CCNA1) |
4-RPD263Hu01 |
Cloud-Clone |
-
EUR 588.79
-
EUR 280.80
-
EUR 1877.95
-
EUR 705.98
-
EUR 1291.97
-
EUR 469.20
-
EUR 4514.88
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Cyclin A1 expressed in: E.coli |
Recombinant Cyclin A1 (CCNA1) |
4-RPD263Hu02 |
Cloud-Clone |
-
EUR 588.79
-
EUR 280.80
-
EUR 1877.95
-
EUR 705.98
-
EUR 1291.97
-
EUR 469.20
-
EUR 4514.88
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Cyclin A1 expressed in: E.coli |
FGF-acidic, Fibroblast Growth Factor-acidic, human |
RC215-12 |
Bio Basic |
50ug |
EUR 183.19 |
|
Recombinant Human Fibroblast Growth Factor-acidic |
7-00319 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human Fibroblast Growth Factor-acidic |
7-00320 |
CHI Scientific |
50µg |
Ask for price |
Recombinant Human Fibroblast Growth Factor-acidic |
7-00321 |
CHI Scientific |
1mg |
Ask for price |
Recombinant Mouse Fibroblast Growth Factor-acidic |
7-00325 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Mouse Fibroblast Growth Factor-acidic |
7-00326 |
CHI Scientific |
50µg |
Ask for price |
Recombinant Mouse Fibroblast Growth Factor-acidic |
7-00327 |
CHI Scientific |
1mg |
Ask for price |
Recombinant human Acidic repeat-containing protein |
P2170 |
FN Test |
100ug |
Ask for price |
|
Description: Recombinant protein for human Acidic repeat-containing protein |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Hu01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Hu02 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Mu01 |
Cloud-Clone |
-
EUR 485.57
-
EUR 253.20
-
EUR 1490.88
-
EUR 576.96
-
EUR 1033.92
-
EUR 400.80
-
EUR 3547.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Mu02 |
Cloud-Clone |
-
EUR 485.57
-
EUR 253.20
-
EUR 1490.88
-
EUR 576.96
-
EUR 1033.92
-
EUR 400.80
-
EUR 3547.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Mu03 |
Cloud-Clone |
-
EUR 485.57
-
EUR 253.20
-
EUR 1490.88
-
EUR 576.96
-
EUR 1033.92
-
EUR 400.80
-
EUR 3547.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Mu04 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Ra01 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant Glial Fibrillary Acidic Protein (GFAP) |
4-RPA068Ra02 |
Cloud-Clone |
-
EUR 496.32
-
EUR 256.80
-
EUR 1531.20
-
EUR 590.40
-
EUR 1060.80
-
EUR 408.00
-
EUR 3648.00
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Glial Fibrillary Acidic Protein expressed in: E.coli |
Recombinant human FGF acidic/FGF1 Protein |
RP01242 |
Abclonal |
10 μg |
EUR 178.8 |
FGF-1/FGF-acidic, human recombinant |
4034-10 |
Biovision |
each |
EUR 164.4 |
FGF-1/FGF-acidic, human recombinant |
4034-1000 |
Biovision |
each |
EUR 2010 |
FGF-1/FGF-acidic, human recombinant |
4034-50 |
Biovision |
each |
EUR 307.2 |
FGF-1/FGF-acidic, murine recombinant |
4035-10 |
Biovision |
each |
EUR 164.4 |
FGF-1/FGF-acidic, murine recombinant |
4035-1000 |
Biovision |
each |
EUR 2010 |
FGF-1/FGF-acidic, murine recombinant |
4035-50 |
Biovision |
each |
EUR 307.2 |
Recombinant Human Annexin A1/ANXA1 |
C093-10ug |
Novoprotein |
10ug |
EUR 242.4 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
Recombinant Human Annexin A1/ANXA1 |
C093-1mg |
Novoprotein |
1mg |
EUR 2739.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
Recombinant Human Annexin A1/ANXA1 |
C093-500ug |
Novoprotein |
500ug |
EUR 1935.6 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
Recombinant Human Annexin A1/ANXA1 |
C093-50ug |
Novoprotein |
50ug |
EUR 595.2 |
Description: Lyophilized from a 0.2 μm filtered solution of 20mM PB, 150mM NaCl, pH 7.2. |
Serum Amyloid A1 Recombinant Protein |
91-546 |
ProSci |
0.05 mg |
EUR 821.4 |
Description: Serum Amyloid A1 Protein (SAA1) is an acute phase apolipoprotein reactant that is produced predominantly by hepatocytes and is under the regulation of inflammatory cytokines. SAA is produced mainly in the liver and circulates in low levels in the blood. SAA may play a role in the immune system and facilitate the repair of injured tissues, it also acts as an antibacterial agent, and signals the migration of germ-fighting cells to sites of infection. SAA also functions as an apolipoprotein of the HDL complex. The SAA cleavage product designated amyloid protein A is deposited systemically as amyloid in vital organs such as the liver, spleen, and kidneys in chronic inflammatory diseases patients. These deposits are extremely insoluble and resistant to proteolysis; they disrupt tissue structure and compromise performance. |
Phospholipase A1 Member A (Recombinant) |
20-abx073438 |
Abbexa |
-
EUR 4101.60
-
EUR 393.60
-
EUR 276.00
|
|
|
Aldehyde Dehydrogenase 3 A1 (Recombinant) |
20-abx073768 |
Abbexa |
-
EUR 393.60
-
EUR 7676.40
-
EUR 276.00
|
|
|
Aldehyde Dehydrogenase 5 A1 (Recombinant) |
20-abx073787 |
Abbexa |
-
EUR 393.60
-
EUR 7676.40
-
EUR 276.00
|
|
|
hnRNP A1 recombinant monoclonal antibody |
A5314 |
Bimake |
100ul X 3 |
EUR 714 |
|
Description: A recombinant monoclonal antibody from rabbit against human hnRNP A1 for WB, IHC, IF,ELISA |
EDA-A1, Soluble Recombinant Protein |
90-288 |
ProSci |
10 ug |
EUR 437.1 |
Description: The TNF family ligand ectodysplasin A (EDA) and its receptor EDAR are required for proper development of skin appendages such as hair, teeth, and eccrine sweat glands. Loss of function mutations in the Eda gene cause X-linked hypohidrotic ectodermal dysplasia (XLHED), a condition that can be ameliorated in mice and dogs by timely administration of recombinant EDA. The Eda gene on the X chromosome is transcribed as multiple splice variants, only two of which code for the receptor-binding C-terminal TNF homology domain. These two variants code for 391- and 389-amino acid-long proteins called EDA1 and EDA2. EDA1 binds EDAR, whereas EDA2 binds to another receptor, XEDAR. The biology of EDA2 and XEDAR is distinct from that of EDA1. Indeed, XEDAR-deficient mice have no obvious ectodermal dysplasia phenotype, whereas mice deficient in EDA, EDAR, or the signaling adaptor protein EDARADD all display virtually indistinguishable ectodermal dysplasia phenotypes, indicating the predominance of the EDA1-EDAR axis in the development of skin-derived appendages. |
Recombinant Carboxypeptidase A1, Pancreatic (CPA1) |
4-RPF315Ra01 |
Cloud-Clone |
-
EUR 612.44
-
EUR 286.80
-
EUR 1966.66
-
EUR 735.55
-
EUR 1351.10
-
EUR 484.80
-
EUR 4736.64
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Carboxypeptidase A1, Pancreatic expressed in: E.coli |
Recombinant Crystallin Beta A1 (CRYbA1) |
4-RPF342Mu01 |
Cloud-Clone |
-
EUR 593.09
-
EUR 282.00
-
EUR 1894.08
-
EUR 711.36
-
EUR 1302.72
-
EUR 472.80
-
EUR 4555.20
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Crystallin Beta A1 expressed in: E.coli |
RT1-A1 Recombinant Protein (Rat) |
RP227045 |
ABM |
100 ug |
Ask for price |
Hba-a1 Recombinant Protein (Mouse) |
RP140990 |
ABM |
100 ug |
Ask for price |
Cyclin A1 (Cyclin A1) Antibody |
20-abx134059 |
Abbexa |
-
EUR 360.00
-
EUR 526.80
-
EUR 226.80
|
|
|
Cyclin A1 (Cyclin A1) Antibody |
20-abx116790 |
Abbexa |
|
|
|
Cyclin A1 (Cyclin A1) Antibody |
20-abx013053 |
Abbexa |
-
EUR 376.80
-
EUR 117.60
-
EUR 477.60
-
EUR 594.00
|
- 100 ug
- 10 ug
- 200 ug
- 300 µg
|
|
Cyclin A1 (Cyclin A1) Antibody |
abx038316-100ug |
Abbexa |
100 ug |
EUR 469.2 |
|
Cyclin A1 (Cyclin A1) Antibody |
abx232120-100ug |
Abbexa |
100 ug |
EUR 577.2 |
|
FGF acidic antibody |
70R-FR007 |
Fitzgerald |
50 ug |
EUR 327.6 |
Description: Affinity purified Rabbit polyclonal FGF acidic antibody |
FGF acidic antibody |
70-FR34 |
Fitzgerald |
50 ug |
EUR 357.6 |
Description: Affinity purified Rabbit polyclonal FGF acidic antibody |
FGF acidic protein |
30R-AF012 |
Fitzgerald |
10 ug |
EUR 159.6 |
Description: Purified recombinant Human FGF acidic protein |
FGF acidic protein |
30R-AF043 |
Fitzgerald |
50 ug |
EUR 327.6 |
Description: Purified recombinant Human FGF acidic protein |
Acidic Cytokeratins Antibody |
abx140335-01mg |
Abbexa |
0.1 mg |
EUR 427.2 |
|
FGF-1, acidic |
PR27011 |
Neuromics |
50 ug |
EUR 381.6 |
anti-Acidic Calponin |
YF-PA23479 |
Abfrontier |
50 ul |
EUR 400.8 |
Description: Mouse polyclonal to Acidic Calponin |
Acidic Cytokeratin Antibody |
V7193-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7193-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7193IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7193SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7198-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7198-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7198IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7198SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7274-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7274-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7274IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V7274SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: There are two types of cytokeratins/keratins/CKs: the acidic type I cytokeratins and the basic or neutral type II cytokeratins. The subsets of cytokeratins which an epithelial cell expresses depends mainly on the type of epithelium, the moment in the course of terminal differentiation and the stage of development. Thus this specific keratin fingerprint allows the classification of all epithelia upon their keratin expression profile. Furthermore this applies also to the malignant counterparts of the epithelia (carcinomas), as the keratin profile tends to remain constant when an epithelium undergoes malignant transformation. The main clinical implication is that the study of the keratin profile by immunohistochemistry techniques is a tool of immense value widely used for tumor diagnosis and characterization in surgical pathology. [Wiki] |
Acidic Cytokeratin Antibody |
V3115-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50 , 48, 46, 45, and 40kDa. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. |
Acidic Cytokeratin Antibody |
V3115-20UG |
NSJ Bioreagents |
20 ug |
EUR 219 |
Description: This mAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50 , 48, 46, 45, and 40kDa. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. |
Acidic Cytokeratin Antibody |
V3115IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 499 |
Description: This mAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50 , 48, 46, 45, and 40kDa. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. |
Acidic Cytokeratin Antibody |
V3115SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 499 |
Description: This mAb recognizes the 56.5kDa (CK10); 50kDa (CK14); 50kDa (CK15); 48kDa (CK16); 40kDa (CK19) keratins of the acidic (Type I or LMW) subfamily. Twenty human keratins are resolved with two-dimensional gel electrophoresis into acidic (pI 6.0) subfamilies. The acidic keratins have molecular weights (MW) of 56.5, 55, 51, 50, 50 , 48, 46, 45, and 40kDa. Many studies have shown the usefulness of keratins as markers in cancer research and tumor diagnosis. |
Recombinant Human Fibroblast Growth Factor-acidic, Sf9 |
7-00322 |
CHI Scientific |
2µg |
Ask for price |
Recombinant Human Fibroblast Growth Factor-acidic, Sf9 |
7-00323 |
CHI Scientific |
10µg |
Ask for price |
Recombinant Human Fibroblast Growth Factor-acidic, Sf9 |
7-00324 |
CHI Scientific |
1mg |
Ask for price |
Proline-Rich Acidic Protein 1 Recombinant Protein |
91-734 |
ProSci |
0.05 mg |
EUR 651.3 |
Description: Proline-rich acidic protein 1, also known as Uterine-specific proline-rich acidic protein, UPA and PRAP1, is a secreted protein. PRAP1 is abundantly expressed in the epithelial cells of the liver, kidney, gastrointestinal tract and cervix. PRAP1 is up-regulated by butyrate, trichostatin A and 5'-aza-2' deoxycytidine. PRAP1 may play an important role in maintaining normal growth homeostasis in epithelial cells. PRAP1 is suppressed through epigenetic mechanisms involving histone deacetylation and methylation. PRAP1 has been shown to cause cell growth inhibition in cancer cell lines. |
Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) |
4-RPA032Hu01 |
Cloud-Clone |
-
EUR 588.79
-
EUR 280.80
-
EUR 1877.95
-
EUR 705.98
-
EUR 1291.97
-
EUR 469.20
-
EUR 4514.88
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Human Fibroblast Growth Factor 1, Acidic expressed in: E.coli |
Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) |
4-RPA032Mu01 |
Cloud-Clone |
-
EUR 642.55
-
EUR 295.20
-
EUR 2079.55
-
EUR 773.18
-
EUR 1426.37
-
EUR 505.20
-
EUR 5018.88
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Mouse Fibroblast Growth Factor 1, Acidic expressed in: E.coli |
Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) |
4-RPA032Ov01 |
Cloud-Clone |
-
EUR 633.95
-
EUR 292.80
-
EUR 2047.30
-
EUR 762.43
-
EUR 1404.86
-
EUR 499.20
-
EUR 4938.24
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Sheep Fibroblast Growth Factor 1, Acidic expressed in: E.coli |
Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) |
4-RPA032Po01 |
Cloud-Clone |
-
EUR 668.35
-
EUR 302.40
-
EUR 2176.32
-
EUR 805.44
-
EUR 1490.88
-
EUR 523.20
-
EUR 5260.80
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Pig Fibroblast Growth Factor 1, Acidic expressed in: E.coli |
Recombinant Fibroblast Growth Factor 1, Acidic (FGF1) |
4-RPA032Ra01 |
Cloud-Clone |
-
EUR 625.34
-
EUR 290.40
-
EUR 2015.04
-
EUR 751.68
-
EUR 1383.36
-
EUR 494.40
-
EUR 4857.60
|
- 100 ug
- 10ug
- 1 mg
- 200 ug
- 500 ug
- 50ug
- 5 mg
|
|
Description: Recombinant Rat Fibroblast Growth Factor 1, Acidic expressed in: E.coli |
Recombinant Mouse FGF1/FGFa/FGF acidic Protein |
RP00487 |
Abclonal |
10 μg |
EUR 174 |
Protein S100-A1 (S100-A1) Antibody |
20-abx110144 |
Abbexa |
-
EUR 493.20
-
EUR 2214.00
-
EUR 718.80
-
EUR 218.40
-
EUR 360.00
|
- 100 ug
- 1 mg
- 200 ug
- 20 ug
- 50 ug
|
|
ES Electrophoresis Casting Tray, 7cm X 14cm |
LE1011-A1 |
GenDepot |
Ea |
EUR 198 |
Liquid Wicks assortment, 15, XF, F,and Medium, 200 of each size |
W-A1 |
MiTeGen |
800 WICKS |
EUR 66 |
|
Description: Liquid Wicks assortment, 15, XF, F,and Medium, 200 of each size |
Coumermycin A1 |
C219-5MG |
TOKU-E |
5 mg |
EUR 310.8 |
Bafilomycin A1 |
A8627-.5 |
ApexBio |
500 µg |
EUR 201.6 |
Description: Bafilomycin A1 is a selective inhibitor of vacuolar H+ ATPases (V-ATPases) with I50 values of 4-400 nmol/mg. |
Bafilomycin A1 |
A8627-1 |
ApexBio |
1 mg |
EUR 331.2 |
Description: Bafilomycin A1 is a selective inhibitor of vacuolar H+ ATPases (V-ATPases) with I50 values of 4-400 nmol/mg. |
Bafilomycin A1 |
A8627-5 |
ApexBio |
5 mg |
EUR 1195.2 |
Description: Bafilomycin A1 is a selective inhibitor of vacuolar H+ ATPases (V-ATPases) with I50 values of 4-400 nmol/mg. |
Enniatin A1 |
E036-1MG |
TOKU-E |
1 mg |
EUR 268.8 |
Enniatin A1 |
E036-5MG |
TOKU-E |
5 mg |
EUR 849.6 |
Leucomycin A1 |
C4182-1 |
ApexBio |
1 mg |
EUR 559.2 |
Description: Leucomycin A1, a major metabolite extracted from the leucomycin complex, is a major macrocyclic lactone antibiotics produced by Streptomyces kitasatoensis. Leucomycin A1 is one of the more potent members of leucomycin complex. |
Leucomycin A1 |
C4182-5 |
ApexBio |
5 mg |
EUR 1688.4 |
Description: Leucomycin A1, a major metabolite extracted from the leucomycin complex, is a major macrocyclic lactone antibiotics produced by Streptomyces kitasatoensis. Leucomycin A1 is one of the more potent members of leucomycin complex. |
A1 antibody |
70R-11802 |
Fitzgerald |
100 ug |
EUR 501.6 |
Description: Rabbit polyclonal A1 antibody |
Antimycin A1 |
A127-0.5MG |
TOKU-E |
0.5 mg |
EUR 326.4 |
Antimycin A1 |
A127-2.5MG |
TOKU-E |
2.5 mg |
EUR 1053.6 |
Bafilomycin A1 |
20-abx076625 |
Abbexa |
|
|
|
Bafilomycin A1 |
B038-1MG |
TOKU-E |
1 mg |
EUR 342 |
Bafilomycin A1 |
B038-5MG |
TOKU-E |
5 mg |
EUR 1108.8 |
Leucomycin A1 |
L031-1MG |
TOKU-E |
1 mg |
EUR 381.6 |
Leucomycin A1 |
L031-5MG |
TOKU-E |
5 mg |
EUR 1248 |
Nystatin A1 |
N044-25MG |
TOKU-E |
25 mg |
EUR 285.6 |
Nystatin A1 |
N044-5MG |
TOKU-E |
5 mg |
EUR 106.8 |
mogroside ?A1 |
N2008-10 |
ApexBio |
10 mg |
EUR 1173.6 |
Description: Extracted from Siraitia grosvenorii (Swingle) C. Jeffrey ex Lu et Z. Y. Zhang dried fruit;Store the product in sealed, cool and dry condition |
Hederacolchiside A1 |
N2047-5 |
ApexBio |
5 mg |
EUR 1173.6 |
Description: Extracted from Pulsatilla chinensis (Bunge) Regel.;Store the product in sealed, cool and dry condition |
Epimedin A1 |
N2231-20 |
ApexBio |
20 mg |
EUR 338.4 |
Description: Extracted from Epimedium brevicornum Maxim. dried parts on the ground;Store the product in sealed, cool and dry condition |
Thymosin a1 |
H-6945.0001 |
Bachem |
1.0mg |
EUR 400.8 |
Description: Sum Formula: C129H215N33O55; CAS# [62304-98-7] net |
Thymosin a1 |
H-6945.0005 |
Bachem |
5.0mg |
EUR 1488 |
Description: Sum Formula: C129H215N33O55; CAS# [62304-98-7] net |
Thymosin a1 |
H-7756.0500 |
Bachem |
0.5mg |
EUR 219.6 |
Description: Sum Formula: C129H215N33O55; CAS# [62304-98-7] net |
Thymosin a1 |
H-7756.1000 |
Bachem |
1.0mg |
EUR 367.2 |
Description: Sum Formula: C129H215N33O55; CAS# [62304-98-7] net |
Quinolactacin A1 |
Q006-1MG |
TOKU-E |
1 mg |
EUR 452.4 |
Quinolactacin A1 |
Q006-5MG |
TOKU-E |
5 mg |
EUR 1492.8 |
Timosaponin A1 |
TB0735-0010 |
ChemNorm |
10mg |
EUR 273.6 |
Hederacolchiside A1 |
TB0828 |
ChemNorm |
20mg |
EUR 273.6 |
Wulignan A1 |
TB0904-0025 |
ChemNorm |
10mg |
EUR 760.8 |
Procyanidin A1 |
TBW00068 |
ChemNorm |
10mg |
EUR 504 |
Ilexsaponin A1 |
TBW00081 |
ChemNorm |
20mg |
EUR 325.2 |
Jionoside A1 |
TBW00336 |
ChemNorm |
10mg |
EUR 580.8 |
Ciwujianoside A1 |
TBW00827 |
ChemNorm |
10mg |
Ask for price |
Cylindrol A1 |
TBZ0220 |
ChemNorm |
unit |
Ask for price |
Epiwuignan A1 |
TBZ0331 |
ChemNorm |
unit |
Ask for price |
Jujuboside A1 |
TBZ0520 |
ChemNorm |
10mg |
Ask for price |
Soyasaponin A1 |
TBZ0874 |
ChemNorm |
unit |
Ask for price |
Tacacoside A1 |
TBZ0922 |
ChemNorm |
unit |
Ask for price |
Jiocarotenoside A1 |
TBZ1509 |
ChemNorm |
unit |
Ask for price |
Meliatoxin A1 |
TBZ1614 |
ChemNorm |
unit |
Ask for price |
Prostaglandin A1 |
TBZ1839 |
ChemNorm |
unit |
Ask for price |
Tjipanazole A1 |
TBZ1982 |
ChemNorm |
unit |
Ask for price |
Teleocidin A1 |
T075-1MG |
TOKU-E |
1 mg |
EUR 381.6 |
Teleocidin A1 |
T075-5MG |
TOKU-E |
5 mg |
EUR 1248 |
Epimedin A1 |
TB0109-0020 |
ChemNorm |
20mg |
EUR 375.6 |
Bacoside A1 |
TBZ2509 |
ChemNorm |
unit |
Ask for price |
Coumermycin A1 |
B2414-1 |
Biovision |
each |
EUR 170.4 |
Coumermycin A1 |
B2414-5 |
Biovision |
each |
EUR 444 |
This assessment primarily focuses on efforts to raised perceive the molecular interplay between host pathogens from each views, in addition to the resistance genes, metabolomic modifications, quantitative trait loci with potential for enchancment in illness resistance and host genome manipulation through transgenic approaches, and it additional identifies analysis gaps and supplies solutions for future analysis priorities.